A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
NCT ID: NCT05523765
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
26 participants
INTERVENTIONAL
2022-11-14
2024-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
NCT01900431
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01095250
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
NCT03155243
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
NCT06085079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Brepocitinib Dose Level 1 by mouth (PO) once daily (QD)
Brepocitinib
Oral Brepocitinib
Brepocitinib Dose Level 2 by mouth (PO) once daily (QD)
Brepocitinib
Oral Brepocitinib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brepocitinib
Oral Brepocitinib
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis).
3. Active uveitic disease as defined by the presence of at least 1 of the following parameters in at least 1 eye, as determined by the investigator:
1. Active, inflammatory chorioretinal and/or retinal vascular lesion; OR
2. ≥2+ vitreous haze grade (NEI/SUN criteria).
4. Receiving up to one non-corticosteroid, non-biologic, immunomodulatory therapy
5. Weight \> 40 kg with a body mass index \< 40 kg/m2.
Exclusion Criteria
2. Has confirmed or suspected current diagnosis of infectious uveitis
3. History of:
* Any lymphoproliferative disorder
* Active malignancy;
* History of cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
4. At risk of thrombosis and cardiovascular disease
5. Have a high risk for herpes zoster reactivation
6. Have active or recent infections
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Priovant Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brendan Johnson, PhD
Role: STUDY_DIRECTOR
SVP, Early Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Palo Alto, California, United States
Clinical Trial Site
Pasadena, California, United States
Clinical Trial Site
Lakewood, Colorado, United States
Clinical Trial Site
Waltham, Massachusetts, United States
Clinical Trial Site
St Louis, Missouri, United States
Clinical Trial Site
Palisades Park, New Jersey, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Eugene, Oregon, United States
Clinical Trial Site
Nashville, Tennessee, United States
Clinical Trial Site
Bellaire, Texas, United States
Clinical Trial Site
Katy, Texas, United States
Clinical Trial Site
Plano, Texas, United States
Clinical Trial Site
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVT-2201-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.